European Archives - Page 26 of 981 - European Medical Journal

Evolving Patient Centered Therapies for Metastatic NSCLC

The metastatic non-small cell lung cancer (mNSCLC) treatment landscape has vastly expanded over the past two decades as a result of…

AI Voice Analysis Detects Early Parkinson’s with 99% Accuracy

AI voice analysis shows 99% accuracy in detecting Parkinson’s disease early, paving the way for better patient care.

Alternative LDL Lowering Strategy as Effective as Statins for Atherosclerosis

Alternative LDL cholesterol-lowering strategy offers similar outcomes to statins, with fewer side effects and better safety.

HIV Then and Now: Advances in Immunity and Vaccination

This week, Jonathan welcomes Mark Connors to explore the advancements in HIV vaccine technology and the progress in global understanding of HIV since the 1980s, highlighting how these insights can inform approaches to other viruses.

Reduced-Dose Steroids Linked to Higher Relapse Risk in ANCA-Associated Vasculitis

Reduced-dose steroids increase relapse and progression risk in ANCA-associated vasculitis, particularly in rituximab-treated patients, study shows.

PCOS Associated with Advanced Maternal Age

Women with polycystic ovary syndrome (PCOS) have fewer children and give birth later in life compared to women without PCOS.

No Survival Benefit for Chemoradiotherapy in Oesophageal Cancer

A new study comparing treatment strategies for stage T2N0M0 oesophageal cancer has revealed no significant survival advantage for patients receiving neoadjuvant chemoradiotherapy followed by surgery.

Nirmatrelvir/Ritonavir Alleviates COVID-19 Symptoms in High-Risk Patients

Nirmatrelvir/ritonavir reduced hospitalisations, symptom duration, and healthcare resource utilisation in high-risk, unvaccinated adults with mild-to-moderate COVID-19.

Could GLP-1 Drugs Reduce Alcohol Consumption?

A systematic review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded some promising results.

Efficacy of Dupilumab in Children with Atopic Dermatitis

At week 16, dupilumab demonstrated significant benefits compared to placebo, regardless of the presence of asthma or AR.